‘A single version of truth’ to accelerate decision making

By Vassia Barba

- Last updated on GMT

(Image: Getty/scyther5)
(Image: Getty/scyther5)

Related tags data analysis Drug development

Trinity’s acquisition of Bell Canyon aims to create an integrated data management offering that will enable all members of a development project to gain access to ‘a single version of truth.’

Trinity, a company providing insights and analytics services to drug developers, announced the acquisition of Bell Canyon Consulting, a developer of data management software.

Through the acquisition, Trinity aims to build on its existing Commercial Data Solutions Suite, and expand it to include early-stage development projects, according to David Fitzhenry, the company’s CEO.

The final data management software product to be developed is expected to facilitate and accelerate the decision making of drug developers, by providing a “tailored execution plan to map information needs,” ​as well as customizable reports and dashboards, the company stated.

Asked about the importance of data management in accelerating drug development, Fitzhenry told us that “Foundationally, good data is critical to inform key decisions being made across the organization, but often hard to effectively manage and govern.”

According to the CEO, enabling cross-functional teams within a drug development organization to access a ‘single version of the truth’ based on aligned metrics and key performance indicators will accelerate decision making.

“This results in greater lead time, as well as to the ability for enhanced planning,” ​he added.

Fitzhenry also told us that while improved data management is a key benefit of the integration, “the combined organization will also enhance business intelligence capabilities, including reporting and analytics.”

Related news

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more